CNC — Deck
Centene is the largest government-sponsored managed care organization in the United States, covering 26 million members across Medicaid, Medicare, and ACA Marketplace programs in 30 states, earning thin but massive margins on $195B in annual revenue.
One quarter of margin recovery vs. a decade of structural thin margins.
- The HBR question. Q1 2026 Medicaid HBR improved 50bps to 93.1%. Management said the improvement was structural — fraud/waste/abuse programs and trend management — not just a mild flu season. At $195B in revenue, every 100bps of HBR improvement generates $1.7B in pretax income. This one variable controls whether CNC earns $3.40 or $6.00.
- The valuation gap. CNC trades at 0.13x revenue — less than half the next-cheapest managed care peer (Molina at 0.26x). Forward P/E of 16x on guided $3.40 adj EPS vs. a 15-year median of 20x. The market is pricing permanent impairment; the cash flow says otherwise ($5.1B OCF in FY2025 despite a $6.7B GAAP loss).
- The credibility gap. FY2025 guidance started at more than $6.00 adj EPS and delivered $2.08 — a 65% miss. One strong quarter does not rebuild institutional trust. The stock has rallied 64% from March lows, but sell-side consensus ($47) still trails the price ($54). Q2 and Q3 HBR will decide if the market is early or wrong.
Cash generation is intact despite the worst GAAP year in a decade.
FY2025's $6.7B GAAP loss was a non-cash goodwill impairment clearing the WellCare overpayment, not an operational collapse. The business generated $5.1B in operating cash flow — a 7:1 ratio of cash to reported earnings. Capital intensity is negligible (capex under 0.5% of revenue). The balance sheet tightened on the impairment (D/E spiked to 0.87x from 0.70x) but actual debt declined by $1.1B, and debt-to-cap improved to 43.2% in Q1 2026 after repaying $1B in senior notes.
The market is pricing $3.40 earnings as a ceiling — the evidence says it is a floor.
- Wrong earnings base. Consensus targets average $47 — below the current price. Analysts are modeling CNC on guided $3.40 adj EPS for FY2026, treating it as normalized. FY2024 delivered $7.17 adj EPS at an 88.3% HBR. If HBR recovers from 91.9% even halfway to 89%, earnings power is $5–6.
- Unpriced structural driver. CMS dual-eligible integration rules (2027–2030) require Medicaid MCO members to receive Medicare through the same parent's D-SNP plan. CNC has the largest Medicaid footprint (30 states) with overlapping Medicare presence — no peer can match this structural enrollment advantage. No analyst model explicitly values this mandate.
- Resolution is near. June 2026 Wakely data determines Marketplace risk adjustment (receivable vs. payable). Q2–Q3 HBR confirms or denies structural margin improvement. By October 2026, the variant view resolves.
Three decades of Medicaid roll-ups, one transformative acquisition, and a painful reset.
The builder. Founder Michael Neidorff spent 30 years assembling the largest government MCO in America — from a single Medicaid contract in Wisconsin to a $195B-revenue, 30-state platform. The 2020 WellCare acquisition ($17B) was the capstone: it doubled membership overnight and created the only national-scale Medicaid-plus-Medicare franchise.
The reset. Neidorff died in November 2022. Sarah London inherited a business mid-integration, navigated COVID continuous enrollment unwind, and then watched FY2025 unravel: behavioral health costs surged, Marketplace APTC subsidies expired, and a $6.7B goodwill impairment confirmed WellCare was overpaid. Adjusted EPS collapsed from $7.17 to $2.08.
The recovery. Q1 2026 marked the inflection. Adjusted EPS of $3.37 beat by $0.50. Guidance was raised. Medicaid HBR improved. The question now: is London's team rebuilding or merely bouncing? The next two quarters will answer.
Three data points in the next five months decide the stock.
- June 2026: Wakely risk adjustment. Marketplace receivable vs. payable. Binary outcome worth $500M+ in pretax income swing. Receivable lifts FY2026 adj EPS toward $4.00+.
- July 2026: Q2 Medicaid HBR. First quarter without flu/weather tailwind. Below 93% confirms structural improvement. Above 93.5% confirms seasonal anomaly.
- October 2026: Q3 HBR + full-year trajectory. Two consecutive quarters of improvement locks in the recovery narrative and attracts consensus upgrades from the stale $47 target.
Lean cautious-long — the valuation is too cheap to ignore, but the recovery needs one more quarter.
- For. At 0.13x revenue and 16x guided earnings, CNC is the cheapest managed care stock in a generation. If HBR normalizes to 89–90%, the stock is worth $85 (15.5x on $5.50 adj EPS) — 58% upside.
- For. $5.1B in FY2025 operating cash flow proves the business model is intact beneath the GAAP impairment. Insiders hold $100M+ in stock and are not selling.
- Against. Operating margins of 1–3% offer zero buffer. FY2025 proved a 360bps HBR spike can wipe an entire year of earnings. OBBBA work requirements create the next membership composition shock in 2027.
- Against. FY2025's 65% guidance miss destroyed credibility. One beat does not rebuild a track record. If Q2 disappoints even modestly, the stock gaps lower.
Watchlist to re-rate: Q2 2026 Medicaid HBR (below 93% = conviction buy); June Wakely risk adjustment data (receivable = Marketplace thesis confirmed); sell-side consensus target migration above $55.